Daily Roundup

BIO.ASX DRO.ASX ADA.ASX CYC.ASX RMS.ASX

Biome Delivers Another Record Quarter as Sales Soar

Biome Australia Limited (ASX: BIO) is on a roll, reporting yet another record in quarterly sales revenue. The microbiome health company raked in a staggering ~$4.6 million in Q2 FY25, beating the market forecast and representing an annualized run rate of $18.4 million.

But that's not all - Biome's first-half sales revenue reached ~$8.9 million, a 48.3% jump compared to the same period last year. The company has achieved an impressive compounded annual growth rate (CAGR) of 70.5% over the past three years, and it's showing no signs of slowing down.

DroneShield Lands Massive $9.7 Million Latin American Contract

In other news, DroneShield Limited (ASX:DRO) has scored a significant win, securing a $9.7 million contract from a major Latin American military customer. This marks the company's first order from an in-country reseller and this particular end customer, highlighting the growing demand for DroneShield's counter-drone solutions in the region.

The order is expected to be delivered and paid for in the first half of 2025, with around 80% of the payment coming before shipping. This development is a testament to DroneShield's global expansion strategy, which has seen the company ramp up its presence in the dynamic Latin American market.

Adacel Technologies to Delist from the ASX

In a move that may surprise some investors, Adacel Technologies Ltd (ASX: ADA) has requested a voluntary suspension of its securities, paving the way for the company's delisting from the ASX on January 8, 2025. This decision was previously approved by Adacel's shareholders, and the suspension will ensure an orderly market until the delisting is finalized.

Cyclopharm Responds to ASX Price Query

Cyclopharm Ltd (ASX: CYC) has addressed an ASX price query, confirming that it is not aware of any undisclosed information that could explain the recent trading in its securities. The company stated that it is complying with its continuous disclosure obligations and carrying on business as usual in line with its disclosed strategy.

Ramelius Resources Delivers Record Underlying Free Cash Flow

Ramelius Resources Ltd (ASX: RMS) has capped off a strong quarter, reporting record quarterly gold production of 85,311 ounces and a record underlying free cash flow of A$174.5 million. The company's cash and gold balance now stands at a healthy A$501.7 million, positioning it well for future growth.

As Ramelius looks ahead, the company is focused on incorporating the findings from ongoing studies at its Eridanus and Mt Magnet operations into an updated Mt Magnet Mine Plan, which is expected to be released in the March 2025 quarter.